Stock Upgrades Today Highlight Top Picks

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  18 Dec 2025
 

•   ABNB  
   
  0.00%
•   AEE  
   
  0.00%
•   AMZN  
   
  0.00%
•   ANNX  
   
  0.00%
•   AOUT  
   
  0.00%

$ABNB RBC Capital upgraded Airbnb from Sector Perform to Outperform, signaling confidence in the ability to capture more market share. The upgrade implies a projected upside of 7.85%, reflecting optimism around post-pandemic travel recovery and robust booking trends. Investors may view this as a moderate growth opportunity, with Airbnb positioned to benefit from sustained demand for short-term rentals and increased consumer travel activity.

$AEE UBS maintained its Buy rating on Ameren, projecting a 16.62% upside. The utility company continues to demonstrate strong operational performance and stable cash flow, supported by a growing renewable energy portfolio and regulated rate base, making it an attractive option for dividend-seeking investors in the near term.

$AMZN Analysts reaffirmed Buy ratings on Amazon.com Inc., with price targets ranging from $270 to $300. Amazon remains a dominant e-commerce and cloud computing player, and investors are focusing on continued revenue growth in AWS and international markets. The stock offers strategic exposure to digital commerce trends and AI-enabled services, supporting its long-term growth narrative.

$ANNX Clear Street initiated a Buy rating on Annexon Inc. with a $17 price target, highlighting progress in developing complement inhibitors for inflammation-related diseases. This biotech pipeline advancement positions it for potential multi-bagger upside, appealing to investors with a higher risk tolerance seeking early-stage innovation exposure.

$AOUT Roth Capital maintained a Buy rating on American Outdoor Brands, projecting an 89.93% upside. The strong market positioning in outdoor sporting goods and firearms, coupled with steady revenue growth, makes it an attractive speculative opportunity, particularly for investors seeking high-growth niches within consumer products.

$ARGX RBC Capital continues to favor argenx SE with an Outperform rating and 13.48% projected upside. The biotech leadership in antibody therapies for rare diseases underlines its potential for steady long-term growth, providing a balance of innovation and relative stability for investors.

$ASTS Scotiabank upgraded AST SpaceMobile to Sector Perform following a 50% market cap pullback. With an unchanged price target of $45.60, the upgrade reflects improved valuation and investor sentiment for the satellite communications company, positioning it for potential rebound gains in the near term.

$ATAI Atai Life Sciences N.V. secured a patent for a social anxiety disorder formulation, supporting a Strong Buy consensus with a 12-month target of $12.71, implying 204% upside. This regulatory milestone highlights the innovative pipeline and potential for significant investor returns in the biotechnology sector.

$AUR Aurora Innovation Inc. carries a Buy rating with a median price target of $12, offering an upside potential of 187.08%. Analyst optimism centers on the autonomous vehicle technology and positioning within the EV ecosystem, making it an intriguing play for growth-focused investors.

$BSX Canaccord Genuity maintains a Buy on Boston Scientific, projecting a 35.74% upside. The robust device portfolio and expanding global presence reinforce its status as a leader in medical technology, appealing to investors seeking stable growth in the healthcare sector.

$CBLL Canaccord Genuity continues to support CeriBell with a Buy rating and 16.65% upside. The company benefits from strong demand for specialized diagnostics and medical solutions, reinforcing a favorable near-term outlook.

$COIN Deutsche Bank initiated coverage on Coinbase Global with a Buy and a 59.50% projected upside. The cryptocurrency exchange stands to gain from increasing digital asset adoption and trading activity, making it a compelling, albeit higher-risk, investment for those tracking crypto market trends.

$CWEN CIBC upgraded Clearway Energy to Outperform with 27.79% projected upside. The renewable-focused utility benefits from a growing clean energy demand, regulatory support, and long-term contract visibility, providing both growth potential and defensive stability for investors.

$DLO Itau BBA initiated coverage on DLocal with an Outperform rating and 25.68% projected upside. The cross-border payment solutions are poised to benefit from accelerating e-commerce in emerging markets, offering strategic exposure to digital payments growth.

$ENOV Canaccord Genuity maintains a Buy on Enovis with 79.49% upside, highlighting strong growth prospects in the medical device sector supported by a solid product pipeline and favorable demographic trends.

$FOLD Citigroup initiated coverage on Amicus Therapeutics with a Buy and 52.79% projected upside. The biopharma pipeline in rare diseases underpins potential multi-bagger returns for investors with a tolerance for early-stage biotech risk.

$HOOD Truist Securities initiated coverage on Robinhood Markets with a Buy and 32.89% projected upside. The fintech platform stands to gain from continued retail trading engagement and potential product expansion, making it attractive for growth-oriented investors.

$MDXG Mizuho maintains an Outperform rating on MiMedx Group, projecting 75.27% upside. The regenerative medicine products and revenue expansion potential position it as a compelling healthcare growth stock.

$MU Bank of America upgraded Micron Technology following a blowout earnings report, reflecting strong AI-driven memory demand. With a robust 20% revenue increase and record margins, the company offers strategic exposure to semiconductor growth and a significant near-term upside opportunity.

$NVDA Analysts maintain Buy ratings on Nvidia Corporation, with price targets up to $275. Nvidia AI and GPU leadership, despite potential volatility in gaming cycles and China demand, underscores long-term growth potential in data centers and AI infrastructure.

$PDLB Ponce Financial upgraded to Strong Buy on growing optimism around earnings prospects. The status signals near-term growth potential for investors focused on regional banking expansion and solid credit fundamentals.

$PLAB Photronics upgraded to Strong Buy, reflecting optimism about earnings prospects. The semiconductor photomask and wafer services provider is strategically positioned to benefit from semiconductor demand cycles, offering potential double-digit upside.

$QUAD Quad/Graphics upgraded to Strong Buy, indicating increasing confidence in the printing and packaging earnings trajectory. Investors may find upside potential as demand for specialized print solutions stabilizes and digital-to-print transitions continue.

$SYRE Citigroup and Mizuho initiated coverage on Spyre Therapeutics with Buy and Outperform ratings, projecting roughly 60% upside. Early-stage biotech innovation and a promising pipeline position it as a high-reward play for risk-tolerant investors.

$UPB Mizuho initiated coverage on Upstream Bio with an Outperform and 80.02% upside. The biotech promising therapies for infectious diseases and strategic R&D investment underpin strong growth potential.

$VITL Needham reiterates Buy on Vital Farms with a 67.41% upside, reflecting strong consumer demand for organic and sustainable food products, positioning it for continued growth in the natural foods segment.

$VVV Roth Capital initiated coverage on Valvoline with a Buy and 32.90% projected upside. The automotive maintenance and lubricants company benefits from both recurring revenue streams and strategic market positioning.

View All Headlines